Brought to you by 
GSK buys Corixa
09 May 2005
Executive Summary
GlaxoSmithKline PLC has agreed to acquire the 92% of its long-time partner, immunotherapeutics company Corixa, it does not already own. The company is paying £2.31 ($4.40) in cash for each of Corixa's common shares or common-share equivalents (a 52% premium to the market average), or about $300mm. It will also assume $100mm of Corixa's outstanding convertible notes (due 2008).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com